热门资讯> 正文

Pyxis Oncology获得800万美元支付出售专利权

2024-03-27 19:43

Pyxis Oncology (NASDAQ:PYXS) said it has completed the sale of its rights to royalties from the commercialization of Beovu and another asset to Novartis for a one-time cash payment of $8 million.
The company will record the $8 million payment in Q1 2024, and will retain rights to three other antibodies in development by Apexigen's licensees.

More on Pyxis Oncology

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis
Pyxis Oncology stock rises as it looks to raise $50M through a private placement
Seeking Alpha’s Quant Rating on Pyxis Oncology
Historical earnings data for Pyxis Oncology
Financial information for Pyxis Oncology

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。